Prostate cancer represents a major health challenge and there is currently no effective treatment once it has advanced to the aggressive, metastatic stage. A new has revealed a key cellular mechanism that contributes to aggressive prostate cancer, and supporting a new clinical trial.
A monthly roundup of research briefs showcasing recent scientific advances led by Beth Israel Deaconess Medical Center faculty.
A team of researchers from UCLA and the University of Toronto have identified a new biomarker found in urine that can help detect aggressive prostate cancer, potentially saving hundreds of thousands of men each year from undergoing unnecessary surgeries and radiotherapy treatments.
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients
The Academy for Eating Disorders (AED) and National Association for Males with Eating Disorders Respond to the Media Coverage of Restrictive Diets as ‘Biohacking’
A new study from researchers at the University of Michigan Rogel Cancer Center finds that the gene FOXA1 overrides normal biology in three different ways to drive prostate cancer. They refer to the three classes as FAST, FURIOUS, and LOUD to reflect their unique features.
New research points toward testosterone-boosting supplements as having little or no known effect
Media are invited to stream this event taking place during NATA’s 70th Clinical Symposia in Las Vegas, 12:00 PM EDT / 9:00 AM PDT
World Trade Center (WTC) responders with prostate cancer showed signs that exposure to dust from the World Trade Center site had activated chronic inflammation in their prostates, which may have contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.
Aria Olumi, MD, Chief of Urologic Surgery at Beth Israel Deaconess Medical Center, explains the importance of men knowing their prostate-specific antigen (PSA) number.
James Heckman, MD, Assistant Medical Director of Healthcare Associates at BIDMC and Aria Olumi, MD, Chief of Urologic Surgery at BIDMC, share tips for improving men's health.
To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.
By age 50, nearly half of men experience some degree of erectile dysfunction. The good news: Several treatment options are available.
Each year, 1M men in the U.S. undergo biopsies for prostate cancer. UCLA physicians have found that a new biopsy method, which includes biopsy guided by magnetic resonance imaging (MRI), can be used together with the traditional method to increase the rate of prostate cancer detection.
With Father's Day coming up, now is a good time for dads to take stock of their health and make sure they're current on screening tests for leading diseases such as cancer, heart disease and diabetes.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. This publication accompanies a presentation today that outlines the study results at the American Society for Clinical Oncology (ASCO). Researchers found that treatment with apalutamide significantly improved overall survival, with a 33% reduction in risk of death compared to standard-of-care therapy. Additionally, this study showed apalutamide significantly delayed disease progression and increased the amount of time until a patient has to receive chemotherapy.
Researchers found just 15 percent of a group of men with early-stage prostate cancer received biopsies and other tests according to active surveillance guidelines from the National Comprehensive Cancer Network.
More than 20 physicians and researchers from Seattle Cancer Care Alliance (SCCA) will present at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL May 31 – June 4, 2019.
At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.
Results reported in Biomicrofluidics promise a new way to detect prostate cancer through a simple device, which forces cell samples through channels less than 10 microns wide. When prostate cancer cells are forced through, the metastatic cells exhibit “blebbing,” and the experiments show that highly metastatic prostate cancer cells are more likely to exhibit blebbing than normal cells or even less-metastatic cells are. The new device could be used in a clinical setting to inexpensively test large numbers of samples.
Production of actinium-227 ramps up for use in a drug to fight prostate cancer that has spread to bone.
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more precise and personalized. This work will be a critical component of a new interdisciplinary research project funded with $1.4 million from the National Institutes of Health (NIH) that seeks to improve radiation therapy for high-risk prostate cancer patients.
In a new study published by European Urology, UCLA researchers and colleagues from ten other institutions examined the protocol for treating aggressive prostate cancer. With aggressive forms of this disease, it is often unclear if radiation therapy should be applied to the prostate alone or to the whole pelvis. The reason a low-dose of radiation may be applied to the whole pelvis is that pelvic lymph nodes may have microscopic cancer cells within them.
Scientists at the Johns Hopkins Kimmel Center say they have affirmed widespread inconsistencies in the use of a common laboratory procedure called immunohistochemical staining, and say the variations are making many laboratory experiments unreliable.
A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumors. Using comprehensive genomic profiling (CGP) to analyze thousands of tumor samples from men with advanced prostate cancers, the researchers identified that 57 percent of the samples evaluated had genomic characteristics that suggested the tumors were candidates for targeted therapies.
Men who delay starting a family have a ticking “biological clock” — just like women — that may affect the health of their partners and children, according to Rutgers researchers.
In mouse models and prostate cancer cell lines, researchers at the University of Michigan have demonstrated the preliminary effectiveness of a new set of compounds that offer a potential advance in the treatment of metastatic castration-resistant prostate cancer — one that appears to avoid many of the usual mechanisms of treatment resistance.
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
Investigators at Rutgers Cancer Institute of New Jersey have found that approximately 30 percent of men with localized prostate cancer may have alterations in DNA damage response pathways.
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.
WASHINGTON – Most Americans harbor positive views about mental health disorders and treatment, according to the results of a survey released today, in recognition of mental health month. The survey was conducted by The Harris Poll on behalf of the American Psychological Association.
UCLA researchers have developed a new artificial intelligence system to help radiologists improve their ability to diagnose prostate cancer. The system, called FocalNet, helps identify and predict the aggressiveness of the disease evaluating magnetic resonance imaging, or MRI, scans, and it does so with nearly the same level of accuracy as experienced radiologists.
Prostate cancer patients in Nashville and Los Angeles are benefiting from a computer-based decision aid that implements the latest study results to tailor treatment options to an individual’s quality-of-life priorities.
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.
The rate of human papillomavirus (HPV) infection is high among young minority gay, bisexual, and other men who have sex with men despite the availability of a vaccine that can prevent the infection, a Rutgers School of Public Health study found.
Researchers in Spain have discovered that a hormone secreted by fat cells that is present at higher levels in women can stop liver cells from becoming cancerous. The study, which will be published April 3 in the ournal of Experimental Medicine, helps explain why hepatocellular carcinoma (HCC) is more common in men, and could lead to new treatments for the disease, which is the fourth leading cause of cancer-related death worldwide.
Long-term testosterone therapy can help men with hypogonadism lose weight and maintain their weight loss, researchers from Germany and the United States report. Ten-year results of the ongoing study will be presented Monday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
Privacy concerns linked to both health facilities and providers are major barriers to increasing the number of men who are tested and treated for HIV in Cote d’Ivoire, suggests new Johns Hopkins Center for Communication Programs (CCP) research. CCP is based at the Johns Hopkins Bloomberg School of Public Health.
Decreased sperm and testosterone production caused by abuse of performing-enhancing hormones may be fully reversible once men stop taking the drugs, but full recovery can take at least nine to 18 months, according to research to be presented Sunday, March 24 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
A new male birth control pill passed tests of safety and tolerability when healthy men used it daily for a month, and it produced hormone responses consistent with effective contraception, according to researchers at two institutions testing the drug. The phase 1 study results was presented Sunday, March 24 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
Exposure to tiny air pollution particles may lead to reduced sperm production, suggests new research in mice to be presented Monday, March 25 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
Androgens stimulate prostate cancer cells to grow. Researchers have discovered a new function of the AR in prostate cells — the AR is imported into and localizes to mitochondria of the cell, where it plays a novel role in regulating multiple mitochondrial processes.
For the first time, scientists have identified compounds found in coffee which may inhibit the growth of prostate cancer. This is a pilot study, carried out on drug-resistant cancer cells in cell culture and in a mouse model;
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center more than $18.4 million for cancer research and faculty recruitment.
UNLV study examines firsthand accounts of new fathers’ experiences with PPD, how it differs from that of women, and how to best remove barriers they face in receiving diagnoses and treatment of the little-known phenomenon.
New research by scientists at the University of Nottingham suggests that environmental contaminants found in the home and diet have the same adverse effects on male fertility in both humans and in domestic dogs.
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified how prostate cancer transforms into a deadly treatment-resistant subtype following treatment with anti-androgen therapy. Their findings—which include the metabolic rewiring and the epigenetic alteration that drives this switch— reveal that an FDA-approved drug holds potential as a NEPC treatment. The research also uncovers new therapeutic avenues that could prevent this transformation from occurring. The study was published in Cancer Cell.
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at MD Anderson
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right